Rheumatology Network's Top 5: November 5, 2022

Published on: 

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending November 5, 2022.

Multicomponent Intervention Program may Improve QoL in Patients with Fibromyalgia

Investigators note that healthcare approaches may benefit from including patient-reported experiences of living with and being treated for fibromyalgia.

COVID-19 Negatively Impacts Physical Activity in Patients with Rheumatic Disease

Investigators aimed to assess self-reported changes in physical activity during the COVID-19 pandemic.

Early Gout Onset, Tophaceous Disease in Men Linked to Risk Alleles

"It may be important to identify genetic variants from a gout genome-wide association study (GWAS) rather than serum urate GWAS, in case these variants have an effect on gout independent of their effect on serum urate.”

Etanercept Effectively Slows, Stops Radiographic Progression in RA, PsA

The PRERA trial was the first real-world, non-interventional study to analyze radiographic progression in patients with RA or PsA treated with etanercept.

Patients with Rheumatoid Arthritis More Likely to Develop Thyroid Dysfunction

“Most thyroid diseases and rheumatoid arthritis are chronic diseases, and unfortunately, early signs of thyroid dysfunction are not specific and are often overshadowed by clinical manifestations of other diseases."